Middle East & Africa Pulmonary Drug Delivery Systems Market Outlook

the middle east and africa pulmonary drug delivery systems market is projected to experience moderate growth in the 2018-2032 forecast period. the rise in the prevalence of chronic respiratory diseases such as copd, asthma, and pulmonary tuberculosis, along with the growing elderly population in the region, are some of the major factors driving the growth of the pulmonary drug delivery systems market in the middle east and africa region. the introduction of innovative and advanced products such as inhalers, nebulizers, pumps, and breath activated drug delivery systems in the middle east and africa markets are the major factors contributing to the growth of the pulmonary drug delivery systems market in the region. the adoption of modern drug delivery systems is anticipated to be the major factor contributing to the growth of the pulmonary drug delivery systems market in the middle east and africa region. key players in the global pulmonary drug delivery systems market in the middle east and africa region are cipla, chiesi, teva pharmaceutical industries, 3m, and boehringer ingelheim. these companies are actively launching newer and advanced products to capture a larger portion of the market share. for instance, boehringer ingelheim launched inhalive, its nebuliser device for treating copd, asthma, and tuberculosis in 2017, in the middle east and africa region. government initiatives and support, especially in the gcc countries, to improve the healthcare infrastructure in the region and encourage citizens to focus on preventive treatment and diagnosis are also expected to drive the growth of the pulmonary drug delivery systems market in the middle east and africa region. also, rising awareness of the benefits of pulmonary drug delivery systems among patients, healthcare professionals, and authorities are further expected to boost the growth of the pulmonary drug delivery systems market in middle east and africa region. however, the high cost associated with these products and the presence of low device penetration in some countries of the middle east and africa region act as restraints to the growth of the pulmonary drug delivery systems market in this region.